Enabling personalised therapeutics
dHealthIQ Digital Therapeutics is a part of a professional treatment prescribed by your doctor, so you can be 100% sure it’s the best treatment tailored for your needs!
Our therapeutics enable patients to take ownership of their treatment under the supervision of clinicians. Digital therapeutics allow patients to monitor their own health on a continuous basis, helping to empower patients to make lifestyle choices that will lead them toward improved health. The involvement of a clinician ensures timely intervention as patients experience health changes, and provides patients with professional support for their recovery, effectively closing the “treatment gap.”
Our therapeutics are based on each individual’s unique data. Treatment programs are tailored to the specific behavior and healthcare needs of each individual requiring chronic care. The adaptive technology adjusts its recommendations as patients modify their behavior so that the health-related advice that patients receive is always in sync with their current health status.
Our therapeutics guide patients' healthcare choices through digitized personalized care programs. Therapies focused on achieving optimal health help patients control and reverse unhealthy behavior and give patients a new way to succeed in the battle against chronic disease.
Our therapies combine the professional expertise of clinicians with instant intuitive recommendations powered by AI technology to drive the treatment process
With a strong focus on blending pharmaceutical remedies with lifestyle and behavioral modifications, the continuous nature of digital therapeutics motivates patients to improve compliance with their treatment regimen.
Our diabetes product is our first digital therapy targeted toward patients diagnosed with Diabetes Mellitus Type 2. The diabetes product is focused on therapeutic monitoring of drug and insulin adherence, as well as behavioral intervention aimed at encouraging patients to increase physical activity, improve their nutrition, get enough sleep, and reduce their stress levels.
Our pipeline of upcoming products includes therapies targeting the cardiometabolic disease area, such as hypertension and cardio rehabilitation.
Since its founding, dHealthIQ has been devoted to the development of a new type of digital therapeutic, designed for patients with chronic diseases and the clinicians who treat them. Our first product, a digital diabetes therapeutic, will complete clinical trials this fall. Development of a follow-on product, aimed at bringing similar technology and digital health monitoring methodology to cardiometabolic disease, is nearing completion.
Researchers, clinicians, healthcare institutions, and pharmaceutical companies interested in collaborating with dHealth or providing feedback on our products can contact the company at: firstname.lastname@example.org